Clinical study of MP plus zoledronic acid therapy in newly diagnosed multiple myeloma excluding stem cell transplantation patients
Not Applicable
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000002158
- Lead Sponsor
- Division of clinial oncology and hematology, Jikei University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Treatment history with bisphosphonate within 3 years. (2) Double cancer (or more) or cancer past history. (3)Uncontrollable any complication or infection. (4) Class III or IV heart disease by NYHA classification. (5) Under pregnancy, breast-feeding. (6) Dental infection (within 4 weeks after dental treatment). (7)Viral hepatitis (HBs antigen or HCV antibody positive) (8) Patient applied other clinical study. (9)Others (inappropriate case)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analysis of skeletal-related events on 48 weeks after treatment.
- Secondary Outcome Measures
Name Time Method Analysis of skeletal-related events on 104 weeks after treatment. Response rate of MP plus zoledronic acid on 48 weeks after treatment. Analysis of bone metabolism marker. Analysis of bone density (L2-L4) using DXA method. Frequency of therapy-related toxicity.